Cross-reactivity between six Enterobacteriaceae complete lipopolysaccharide core chemotypes

Journal of Medical Microbiology

Volumn 48, Issue 5, 1999, Pages 433-441

  Nnalue, Ndubisi A ^a,b   Khan, G Nasser ^a   Mustafa, Nada ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b Tonna Bioservices and Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTISERUM; HYPERIMMUNE GLOBULIN; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CROSS REACTION; ENTEROBACTERIACEAE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA CHOLERAESUIS;

ESCHERICHIA COLI; SALMONELLA CHOLERAESUIS;

EID: 0032808595     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-48-5-433     Document Type: Article

References (35)

1. 1. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 1988; 57: 505-518.
2. 2. Chedid L, Parant M, Parant F, Boyer F. A proposed mechanism for natural immunity to enterobacterial pathogens. J Immunol 1968; 100: 292-301.
3. 3. Lyman MB, Stocker BAD, Roantree RJ. Evaluation of the immune response directed against the Salmonella antigenic factors O4,5 and O9. Infect Immun 1979; 26: 956-965.
4. 4. McCabe WR. Immunization with R mutants of S. minnesota, 1. Protection against challenge with heterologous Gram-negative bacilli J Immunol 1972; 108; 601-610.
5. 5. Muotiala A, Hovi M, Mäkelä PH. Protective immunity in mouse salmonellosis: comparison of smooth and rough live and killed vaccines. Microb Pathog 1989; 6: 51-60.
6. 6. Nys M, Cloes JM, Demonty J, Joassin L. Protective effects of polyclonal sera and of monoclonal antibodies active on Salmonella minnesota Re595 lipopolysaccharide during experimental endotoxemia. J Infect Dis 1990; 162: 1087-1095.
7. 7. Ziegler EJ, McCutchan JA, Fierer J et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307: 1225-1230.
8. 8. Greissman SE, Johnston CA. Evidence against the hypothesis that antibodies to the inner core of lipopolysaccharides in antisera raised by immunization with enterobacterial deep-rough mutants confer broad-spectrum protection during gram-negative bacterial sepsis. J Endotox Rex 1977; 4: 123-153.
9. 9. Ng A-K, Chen LH, Chang C-M, Nowotny A. Relationship of structure to function in bacterial endotoxins: serologically cross-reactive components and their effect on protection of mice against some gram-negative infections. J Gen Microbiol 1976; 94: 107-116.
10. 10. Peter G, Chernow M, Keating MH, Ryff JC, Zinner SH. Limited protective effect of rough mutant antisera in murine Escherichia coli bacteremia. Infection 1982; 10: 228-232.
11. 11. van Dijk WC, Verbrugh HA, van Erne-van der Tol ME, Peters R, Verhoef J. Escherichia coli antibodies in opsonisation and protection against infection. J Med Microbiol 1981; 14: 381-389.
12. 12. Bennett-Guerro E, Ayuso L, Hamilton-Davies C et al. Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA 1997; 277: 646-650.
13. 13. Freeman R, Gould FK. Prevention of fever and gram negative infections after open heart surgery by antiendotoxin. Thorax 1985; 40: 846-848.
14. 14. Goldie AS, Fearon KCH, Ross JA et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 1995; 274: 172-177.
15. 15. Gould FK, Harvey JA, Dytrych JK. Antibody to endotoxin is associated with decreased frequency of postoperative infection. Am J Obstet Gynecol 1989; 160: 317-319.
16. 16. Hamilton-Davies C, Barclay GR, Machin SJ, Webb AR. Relationship between endotoxin immune status and outcome following cardiac valve surgery. Br J Anaesth 1995; 74 Suppl: S34.
17. 17 Nnalue NA, Lind SM, Lindberg AA. The disaccharide L-α-D-Heptose 1 → 7-L-α-D-Heptose 1 → of the inner core domain of Salmonella lipopolysaccharide is accessible to antibody and is the epitope of a broadly reactive monoclonal antibody. J Immunol 1992; 149: 2722-2728.
18. 18. Di Padova FE, Brade H, Barclay GR et al. A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect Immun 1993; 61: 3863-3872.
19. 19. Rietschel ETh, Seydel U, Zahringer U et al. Bacterial endotoxin: molecular relationship between structure and activity. Infect Dis Clin North Am 1991; 5: 753-779.
20. 20. Jansson P-E, Lindberg AA, Lindberg B, Wollin R. Structural studies of the hexose region of the core in lipopolysaccharides from Enterobacteriaceae. Eur J Biochem 1981; 115: 571-577.
21. 21. Holst O, Brade H. Chemical structure of the core region of lipopolysaccharides. In: Morrison DC, Ryan JL (eds) Bacterial endotoxin lipopolysaccharides, vol 1. Molecular biochemistry and cellular biology. Boca Raton, CRC Press. 1992; 135-170.
22. 22. Nnalue NA, Lindberg AA. Salmonella choleraesuis strains deficient of O antigen remain fully virulent for mice by parenteral inoculation but are avirulent by oral administration. Infect Immun 1990; 58: 2493-2501.
23. 23. Wilkinson RG, Gemski P, Stocker BAD. Non-smooth mutants of Salmonella typhimurium: differentiation by phage sensitivity and genetic mapping. J Gen Microbiol 1972; 70: 527-554.
24. 24 Westpbal O, Jann K. Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Methods Carbohydr Chem 1969; B5: 80-91.
25. 25. Galanos C, Lüderitz O, Wesphal O. A new method for the extraction of R lipopolysaccharides. Eur J Biochem 1969; 9: 245-249.
26. 26. Galanos C, Lüderitz O, Electrodialysis of lipopolysaccharides and their conversion to uniform salt forms. Eur J Biochem 1975; 54: 603-610.
27. 27. Freudenberg M, Fomsgaard A, Mitov I, Galanos C. ELISA for antibodies to lipid A, lipopolysaccharides and other hydrophobic antigens. Infection 1989; 17: 322-328.
28. 28. Tsai C-M, Frasch CE. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem 1982; 119: 115-119.
29. 29. Dunn DL, Ferguson RM. Immunotherapy of gram-negative bacterial sepsis: enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5. Surgery 1982; 92: 212-219.
30. 30. Marks MI, Ziegler EJ, Douglas H, Corbeil LB, Brande AI. Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide. J Clin Invest 1982; 69: 742-749.
31. 31. Lind SM, Carlin NIA, Lindberg AA. Production and characterization of KDO-specific monoclonal antibodies recognizing lipopolysaccharides from heptoseless mutants of Salmonella. FEMS Microbiol Lett 1985; 28: 45-49.
32. 32. Young LS, Stevens P, Ingram J. Functional role of antibody against "core" glycolipid of Enterobacteriaceae. J Clin Invest 1975; 56: 850-861.
33. 33. Ziegler EJ, McCutchan JA, Douglas H, Braude AI. Prevention of lethal pseudomonas bacteremia with epimerase deficient E. coli antiserum. Trans Assoc Am Physicians 1975; 88: 101-108.
34. 34. Siber GR, Kania SA, Warren HS. Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria. J Infect Dis 1985; 152: 954-964.
35. 35. Shenep JI., Gigliotti F, Davis DS, Hildner WK. Reactivity of antibodies to core glycolipid with gram-negative bacteria. Rev Infect Dis 1987; 9 Suppl 5: S639-S643.